FF-10502, an Antimetabolite With Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells

Journal of Pharmacology and Experimental Therapeutics - United States
doi 10.1124/jpet.118.248740
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

Targeting the Warburg Effect With a Novel Glucose Transporter Inhibitor to Overcome Gemcitabine Resistance in Pancreatic Cancer Cells

Carcinogenesis
MedicineCancer Research
2014English

P8 Is a New Target of Gemcitabine in Pancreatic Cancer Cells

Clinical Cancer Research
Cancer ResearchOncology
2006English

Targeting Pancreatic Cancer Stem Cells

Journal of Cancer Sciences
2015English

Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Cyclopentenyl Cytosine Increases Gemcitabine Radiosensitisation in Human Pancreatic Cancer Cells

British Journal of Cancer
Cancer ResearchOncology
2008English

Loss of PDPK1 Abrogates Resistance to Gemcitabine in Label-Retaining Pancreatic Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine

Clinical Cancer Research
Cancer ResearchOncology
2004English

Aspirin Inhibits Proliferation of Gemcitabine-Resistant Human Pancreatic Cancer Cells and Augments Gemcitabine-Induced Cytotoxicity

Acta Pharmacologica Sinica
MedicinePharmacology
2009English

A Novel Oncolytic Adenovirus Targeting to Telomerase Activity in Tumor Cells With Potent

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy